-
Documents issued in many provinces, the management of traditional Chinese medicine formula particles will continue to be stricter
Time of Update: 2021-10-01
It is worth noting that with the continuous expansion of the TCM formula granule market, in order to strengthen the management of TCM formula granules, standardize the production of TCM formula granules, and guide the healthy development of the industry, the State Food and Drug Administration issued the "Regarding the End of TCM Formula Granules" in February this year.
-
With favorable policies, the health of the pharmaceutical retail industry will continue to improve
Time of Update: 2021-10-01
However, it should be noted that under the background of policy guidance, health industry upgrades, and changes in consumer demand that promote the acceleration of the development of the pharmaceutical retail industry, this market is actually facing many new challenges .
-
Fuhong Henlius submits an application for new indications of anti-PD-1 monoclonal antibody
Time of Update: 2021-10-01
Text|Pharmaceutical Mission HillsOn September 16, the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China announced that Fuhong Henlius had submitted a new indication application for the anti-PD-1 monoclonal antibody slulimumab injection and was accepted .
-
The chain pharmacy was fined 220,000 yuan for purchasing drugs abnormally
Time of Update: 2021-10-01
The above behavior violates the provisions of Article 55 of the Drug Administration Law, that is, drug marketing authorization holders, drug manufacturers, drug trading companies, and medical institutions shall purchase drugs from drug marketing license holders or enterprises with qualifications for drug production and marketing.
-
Keji Pharmaceutical's CT041 CAR-T treatment of digestive system tumors and advanced gastric cancer efficacy data is eye-catching
Time of Update: 2021-10-01
Solid tumor CAR-T debuts with ESMO clinical treatment data for advanced gastric cancerThe study presented in the 2021 ESMO oral report is a clinical trial initiated by a multi-center, open-label Phase I investigator in China.
-
The biological products sector performed outstanding performance in the first half of the year. Revenue increased by nearly 36% year-on-year
Time of Update: 2021-10-01
. Watson Biological released the 2021 semi-annual report on the evening of August 27, stating that the company achieved double growth in revenue and profits in the first half of the year, of which operating income was 1.
-
ESMO 2021 CStone Pharmaceuticals announces the clinical data of the Chinese registration bridging study of Afnib in patients with relapsed/refractory acute myeloid leukemia who are susceptible to IDH1 mutations
Time of Update: 2021-10-01
Efficacy data show that Avonib has excellent clinical efficacy in the treatment of adult Chinese patients with relapsed or refractory acute myeloid leukemia (R/R AML) who are susceptible to IDH1 mutat
-
In the first eight months, domestic manufacturing investment increased by 15.7% year-on-year, and the pharmaceutical industry actively embraced opportunities
Time of Update: 2021-10-01
From the perspective of national and local policies, intelligence, digitization, and greenization will be the new requirements for the high-quality development of the entire manufacturing industry, and the same is true in the pharmaceutical equipment industry .
-
Transplant drugs have become a new trend, and pharmaceutical giants are scrambling to enter the game
Time of Update: 2021-10-01
This drug is mainly used to treat patients with chronic graft-versus-host disease (cGVHD) aged 12 years and above.
In addition, Novartis and Incyte's JAK inhibitor Jakafi (ruxolitinib) was approved in May this year for the treatment of steroid-refractory acute graft-versus-host disease .
-
BeiGene receives positive opinions from the European Medicines Agency's Committee for Human Medicines (CHMP) on the treatment of adult patients with Fahrenheit's macroglobulinemia
Time of Update: 2021-10-01
Beijing, China, Basel, Switzerland and Cambridge, Massachusetts, September 17, 2021/PRNewswire/ - BeiGene (Nasdaq: BGNE; Hong Kong Stock Exchange: 06160) today announced the European Medicines Management The Committee on Medicines for Human Use (CHMP) of the Agency (EMA) recommends approval of Baiyueze® (Zebutinib) for adult patients with Waldenstrom's macroglobulinemia (WM) who have previously received at least one treatment, or as an unsuitable chemical First-line treatment options for immunotherapy of WM patients .
-
Another insulin will be on the market, intensifying market competition is inevitable
Time of Update: 2021-10-01
Recently, Hisun Pharmaceuticals issued an announcement stating that it received the "Drug Registration Certificate" for insulin aspart injection approved and issued by the National Medical Products Administration on September 13, 2021.
-
Many provinces and cities have issued documents, and the transfer of local medical insurance supplements has entered a critical period
Time of Update: 2021-10-01
Among them, according to the notice issued by the Xinjiang Medical Insurance Bureau, it is clear that starting from January 1, 2022, the "Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" will be added to the non-ethnic medicines All 305 varieties were transferred out of the scope of medical insurance payment .
-
Domestic pharmaceutical companies are accelerating the improvement of innovation capabilities through "bringing in"
Time of Update: 2021-10-01
According to the terms of the agreement, Genting Shining will pay SinoVision and China Antibodies an advance payment of US$12 million and a total of US$549 million in future development, registration and commercialization milestone payments, as well as high single-digit global net sales.
-
After domestically-made innovative drugs have entered the medical insurance one after another, manufacturers are facing two major challenges!
Time of Update: 2021-10-01
Recently, Tofflon also mentioned in its response to investors in the disclosed investor relations activity record sheet that domestically-made innovative drugs have entered medical insurance one after another, prompting downstream pharmaceutical companies to pay more attention to operating costs and the stability of the supply chain of production equipment and related materials.
-
Wise Pharma's business spans comparable to WuXi AppTec. Why is it the second-to-last in the industry?
Time of Update: 2021-10-01
Major shareholders' equity after the acquisition of Ruizhi Chemical in 2018Source: Wise Pharmaceutical Announcement ContentIn June 2019, Quantum Biology announced that in order to be more conducive to the company's strategic development and personal needs, the former chairman Zeng Xianjing resigned as chairman, and Huixin was elected as the new chairman by the company's board of directors .
-
The remission rate is 17.3% higher than that of monotherapy!
Time of Update: 2021-10-01
New data shows that the combination of KRAS G12C inhibitor Lumakras (sotorasib) and Amgen Anti-EGFR monoclonal antibody Vectibix (panitumumab) has encouraging efficacy and safety .
This dose exploration and dose expansion cohort study enrolled 31 patients with KRAS G12C mutation metastatic CRC who had received extensive pretreatment (median 2 front-line therapy; range 1-10) .
-
The domestic CRO development momentum continues to be strong, showing two major development trends
Time of Update: 2021-10-01
From an overall point of view, the industry believes that domestic CRO companies are gradually occupying an advantageous position in the global innovative drug industry chain transfer wave, and ushering in more benefits, relying on the advantages of engineer dividends and integrated platform services .
-
Starting from September 20th, 61 medicines in Tianjin have been reduced in price!
Time of Update: 2021-10-01
According to the statistics of contracted purchases in Tianjin, it is estimated that 265 million yuan of medicine purchase costs can be saved each year, which will effectively reduce the burden of medication for patients .
-
Special rectification of online pharmacies is coming
Time of Update: 2021-10-01
The briefing stated that since the launch of the special action, all units in the city have arranged 1,059 drug online sales entities, and have inspected 19 wholesale companies, 820 retail companies and 1 Internet drug trading third-party platform for drug network operations .
-
Insulin national procurement is about to start, these companies will be greatly affected
Time of Update: 2021-10-01
After the relevant pharmaceutical companies win the bid, they often need to increase their production capacity to meet market demand; in this context, more efficient and safer insulin production equipment is also required.
